Status:
NOT_YET_RECRUITING
A Study to Observe the Safety, Tolerability, and Efficacy of Remodulin
Lead Sponsor:
Excelsior
Conditions:
Pulmonary Arterial Hypertension
Eligibility:
All Genders
Brief Summary
This is a multi-center, single-arm, prospective study to enroll patients diagnosed as pulmonary arterial hypertension. The objective in this study is to observe the efficacy and safety of treprostinil...
Detailed Description
This is a multi-center, single-arm, prospective study to enroll patients diagnosed as pulmonary arterial hypertension. The expected study period will be 2 years. PAH patients, who met NHI criteria, to...
Eligibility Criteria
Inclusion
- Diagnosed with symptomatic idiopathic or heritable PAH classified as WHO functional class III and IV symptoms.
- PAH patient, who met NHI criteria, will be scheduled to receive subcutaneous/intravenous treprostinil treatment.
- Ability to adhere to the study visit schedule and understand and comply with all protocol requirements.
- Will provide completed and signed written informed consents
Exclusion
- Active treatment with injectable prostanoids different from subcutaneous/intravenous treprostinil
Key Trial Info
Start Date :
October 16 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2029
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06603285
Start Date
October 16 2025
End Date
December 31 2029
Last Update
August 15 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.